Table 1: Clinical features of MG patients included in the study.

Patient Group 1Hyperplasia (n = 3)Thymitis (n = 3)Involuted (n = 4)

Sex (F/M)
Age at disease onset (years) mean ± SD
Age at surgery (years) mean ± SD
Ab AChR-positive234
Seronegative100
Immunosuppressive therapy224

Patient Group 2Hyperplasia ( )Thymitis ( )Involuted ( )

Sex (F/M)5/15/14/1
Age at disease onset (years)a mean ± SD
Age at surgery (years) mean ± SD
Ab AChR-positive64b4
Seronegative011
Immunosuppressive therapy5c45

Patient Group 3Hyperplasia ( )Thymitis ( )Involuted ( )

Sex (F/M)8/14/13/2
Age at disease onset (years)d mean ± SD
Age at surgery (years) mean ± SD
Ab AChR-positive645
Seronegative310
Immunosuppressive therapy345

aAge at disease onset was not available for two patients, one with hyperplasia and one with thymitis. bInformation on autoantibody presence in serum was not available in one patient. cData on the therapy before thymectomy were missing in one patient. dAge at disease onset was not available for two patients, one with hyperplasia and one with involuted thymus.